Orion Oyj (ORINY) to Issue Dividend of $0.45 on April 29th

Orion Oyj (OTCMKTS:ORINY) announced a dividend on Monday, March 17th, NASDAQ Dividends reports. Stockholders of record on Monday, April 7th will be given a dividend of 0.4478 per share on Tuesday, April 29th. The ex-dividend date is Monday, April 7th. This is a 86.2% increase from Orion Oyj’s previous dividend of $0.24.

Orion Oyj Price Performance

OTCMKTS ORINY opened at $29.76 on Wednesday. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. Orion Oyj has a 1-year low of $17.50 and a 1-year high of $30.25. The company has a 50 day moving average of $26.95 and a 200-day moving average of $25.50. The company has a market cap of $8.40 billion, a price-to-earnings ratio of 23.62 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The business had revenue of $463.41 million during the quarter. On average, equities research analysts expect that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Nordea Equity Research cut shares of Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.